The concern of generic rivalry has repeatedly loomed over copyright’s iconic drug, Viagra, sparking questions about the prospects of related pharmaceutical investments. While first times saw significant profits, the intellectual property lapse has created the door for cheaper alternatives, likely diminishing revenue and creating a significant ris